Specify a stock or a cryptocurrency in the search bar to get a summary
Hillevax Inc
HLVXHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118
Analytics
WallStreet Target Price
3 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures HLVX
Dividend Analytics HLVX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HLVX
Stock Valuation HLVX
Financials HLVX
Results | 2019 | Dynamics |